Land­ing a re­duced 20% tar­iff rate will re­quire phar­ma com­pa­nies to fill out ex­ten­sive pa­per­work and be close­ly mon­i­tored by the De­part­ment of Com­merce.

Pres­i­dent...

As the Iran war en­ters its third month, its knock-on ef­fects on raw ma­te­ri­als, en­er­gy costs and ship­ping are be­gin­ning to be felt in the...

Mer­ck KGaA ap­pears to have a big-pic­ture view of how the Iran war is af­fect­ing the phar­ma in­dus­try so far.

The Ger­man com­pa­ny is see­ing...

Dai­ichi Sankyo is scrap­ping plans to build an­ti­body-drug con­ju­gate man­u­fac­tur­ing ca­pac­i­ty and record­ed an "ex­tra­or­di­nary loss" of 149.4 bil­lion Japan­ese yen ($950 mil­lion) af­ter over­promis­ing...

CSL's stock hit its low­est price since ear­ly 2017 on Mon­day af­ter it low­ered its full-year rev­enue guid­ance by about 4% and said it would...

The Crit­i­cal Med­i­cines Act reached its next mile­stone on Tues­day, af­ter the Eu­ro­pean Par­lia­ment and the Coun­cil pro­vi­sion­al­ly vot­ed it through.

The pro­posed reg­u­la­tion aims...

French vac­cine mak­er Val­ne­va is lay­ing off 10% to 15% of its work­force and re­duc­ing rev­enue pro­jec­tions due to "an emerg­ing ad­verse trend in trav­el...